Being Positive?
March 24, 2006 – Kathy LaTour
A Mission-Driven Life
March 24, 2006 – Kathy LaTour
The Waiting Room
March 24, 2006 – Catherine Kanjer Kapphahn
Losing One’s Right to Complain
March 24, 2006 – Cary Vera-Garcia
Negative Thinking Not Necessarily Depression
March 24, 2006 – Elizabeth Whittington
Fighting Cancer One Colon at a Time
March 24, 2006 – Jeannette Keton
Herceptin in the Spotlight
March 24, 2006 – Monica Zangwill, MD
Maneuvering the Maze of Medicare Part D
March 24, 2006 – Sam Jaffe
Picking Up Momentum for Treating Renal Cell Carcinoma
March 24, 2006 – Beverly A. Caley
Message from the Editor
March 24, 2006 – Vinay Jain, MD
A New Survivor's Club
March 24, 2006 – Jennifer Haupt
Letters from Our Readers
March 24, 2006
Drug Company Questions Marketing of Bioidentical Hormones
March 24, 2006 – Noble Sprayberry
Mixing Supplements with Cancer Therapy
March 24, 2006 – Christie L. Carter
Lost and Found
March 24, 2006 – Jodi Leas
Cancer & Medicare Part D
March 24, 2006 – Diane Blum, Executive Director of Cancercare
Pathway to Herceptin Success
June 08, 2009 – Monica Zangwill, MD
In the Beginning
June 08, 2009 – Dennis Slamon, MD, PhD
Web Exclusive: A Dangerous Side Effect
June 09, 2009 – Elizabeth Whittington
Web Exclusive: Q&A with Dr. Dennis Slamon
June 09, 2009 – Elizabeth Whittington
Staging Kidney Cancer
June 22, 2009
Taking a Closer Look
June 22, 2009 – Elizabeth Whittington
An Unpleasant Surprise
June 22, 2009
Novel Cytokines for RCC
June 22, 2009 – Beverly A. Caley
How Part D Came to Be
June 22, 2009 – Sam Jaffe
Recommended Resources
June 22, 2009
Supporting Co-Survivors
June 22, 2009
Co-Survivor Essays
June 22, 2009
Closer to Relief
March 24, 2006 – Elizabeth Whittington
Easing Bone Pain
June 22, 2009 – Elizabeth Whittington
Quick Relief for Breakthrough Pain
June 22, 2009 – Elizabeth Whittington
House Call
March 24, 2006 – Henry Q. Xiong, MD, PhD
March 24, 2006 – Kathy LaTour
People and Places
March 24, 2006 – Elizabeth Whittington
Currently Viewing
Kidney, Head and Neck Cancers & MDS
March 24, 2006 – Elizabeth Whittington

Kidney, Head and Neck Cancers & MDS

Revlimid is approved for certain types of myelodysplastic syndrome, and Sutent was approved for both advanced kidney cancer and gastrointestinal stromal tumor.

BY Elizabeth Whittington
PUBLISHED March 24, 2006

After positive results in a phase III trial and a recommendation from the Food and Drug Administration’s Oncology Drugs Advisory Committee, Revlimid (lenalidomide) was approved in late 2005 for certain types of myelodysplastic syndromes (MDS), a variety of blood disorders that can cause low blood counts, including anemia, which require frequent blood transfusions.

Revlimid is especially effective in a quarter of MDS patients who carry a specific chromosome 5 deletion. Taken orally, Revlimid can cause many of these patients to no longer need blood transfusions, improving their quality of life. A phase III trial showed Revlimid, a derivative of Thalomid (thalidomide), allowed two thirds of patients to become transfusion-independent for more than a year. Though no trial has shown a risk of birth defects in patients taking Revlimid, the drug is currently only available through a restricted distribution program called RevAssist, which requires doctors and pharmacists to register in order to prescribe the drug. Women must have regular pregnancy tests, and both men and women must use contraceptives.

In addition to MDS, Revlimid has also shown activity in patients with relapsed multiple myeloma. The FDA is considering the drug for multiple myeloma and is expected to approve Revlimid for that indication in mid-2006. It is also being tested in metastatic melanoma and chronic lymphocytic leukemia. Common side effects of Revlimid include neutropenia, fatigue and diarrhea.

For more information, visit

The FDA approved a new oral drug called Sutent (sunitinib) in January for both advanced kidney cancer as well as a rare type of sarcoma of the stomach called gastrointestinal stromal tumor (GIST). The approval made Sutent the first drug to be simultaneously approved for two cancers.

Sutent blocks the activity of multiple enzymes (called tyrosine kinases) that are involved in transmitting signals from the outside to the inside of the cancer cell. Sutent can block the development of new blood vessels (called angiogenesis), essentially starving the tumor of blood and nutrients (see “Picking Up Momentum for Treating Renal Cell Carcinoma,”). In phase II trials, Sutent shrank tumors by at least a third in up to 37 percent of advanced kidney cancer patients.

GIST is a rare tumor that occurs in the stomach and other parts of the digestive system. Fortunately, most GIST patients respond to Gleevec (imatinib), but over time, some patients become resistant to Gleevec and need an alternative treatment. When used against Gleevec-resistant GIST, Sutent had significant activity, prolonging time to tumor progression from six weeks to 27 weeks when compared with placebo. The most commonly reported side effects include fatigue, diarrhea and a rash on the hands and feet.

For more information on Sutent, go to

Erbitux (cetuximab) received approval from the FDA on March 1 for head and neck cancer, a second approval for the monoclonal antibody, which is already on the market for treating metastatic colorectal cancer in combination with Camptosar (irinotecan). In 2005, nearly 40,000 Americans were diagnosed with head and neck cancer, including cancers of the tongue, mouth, salivary glands, throat and voice box.

In colorectal, head and neck and other cancers, the number of receptors for epidermal growth factors is higher on the surface of cancer cells than normal cells. When Erbitux binds to the epidermal growth factor receptor on cancer cells, it inhibits the signal for cancer cell growth. In one of the largest phase III studies ever conducted in head and neck cancer patients, Erbitux in combination with radiation prevented the spread of cancer more effectively than radiation alone and improved median survival by nearly two years.

Other studies show Erbitux is effective in patients whose cancers don’t respond to platinum-based therapy, such as Paraplatin (carboplatin) and Platinol (cisplatin). The most common side effect with Erbitux is an acne-like rash.

For more information on Erbitux, go to

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Gastrointestinal stromal tumor CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In